FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Circadian Reset

Sleep Optimizationintermediate

78

상호작용

78
Share
펩타이드

3

일 평균 mcg

5,400

수준

intermediate

추가됨

May 17, 2026

개요

The Circadian Reset protocol addresses disrupted sleep-wake cycles through a multi-target approach that normalizes both the circadian oscillator and the downstream hormonal rhythms it controls. DSIP serves as the direct sleep promoter, facilitating delta-wave sleep onset and reducing the hyperarousal that prevents circadian entrainment. In shift workers and individuals with delayed sleep phase, DSIP helps establish a consistent sleep onset time by providing a reliable pharmacological "sleep gate" that the body can then entrain around. Epithalon''s role in this stack extends beyond its telomere-related effects to its documented influence on pineal gland function. Professor Khavinson''s research demonstrated that Epithalon normalizes melatonin production in elderly patients whose pineal glands had calcified and atrophied with age. By restoring melatonin synthesis to youthful levels, Epithalon helps re-establish the master circadian signal that synchronizes peripheral tissue clocks throughout the body. The 10-day evening administration cycle targets the pineal gland during its active phase (melatonin synthesis peaks at night), providing both immediate melatonin support and long-term pineal restoration. Morning Selank administration addresses the cortisol-awakening response and daytime alertness — the other half of circadian health. By reducing anxiety and normalizing stress hormones during the day, Selank prevents the evening cortisol elevation that is one of the most common causes of sleep-onset insomnia. Proper daytime alertness (supported by healthy cortisol rhythm) is as important to circadian health as nighttime sleep — the system requires contrast between active and rest phases. This stack is intermediate-level because it requires coordinated timing across three administration windows and includes the cyclical Epithalon component that requires scheduling awareness.

용량 프로토콜

DSIP

nightly· subcutaneous

DSIP에 대한 자세한 내용 →

100 mcg

1회 용량당

Epithalon

nightly (10-day cycle)· subcutaneous

Epithalon에 대한 자세한 내용 →

5,000 mcg

1회 용량당

300 mcg

1회 용량당

목표 및 증거

Circadian rhythmMelatonin regulationSleep qualityDaytime alertnessStress
증거 등급:동물 연구

경고

  • Epithalon and DSIP were removed from the FDA Category 2 list (April 2026) but remain pending PCAC review — not legal to compound yet. This combination targets both pineal function (Epithalon/DSIP) and daytime stress (Selank). Experimental protocol.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.